Key Insights

Highlights

Treatment Research

3 treatments under study, led by Cytarabine

Related Conditions

Often studied with 6 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Active Not Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT04891757Phase 1Active Not RecruitingPrimary

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

Showing all 1 trials

Research Network

Common Treatments

  • Cytarabine1
  • Fhd2861
  • Decitabine1

Active Sponsors

  • Foghorn Therapeutics Inc.1

Top Investigators

Related Conditions

  • Refractory Acute Myeloid Leukemia1
  • Refractory Myelodysplastic Syndromes1
  • Relapsed Acute Myeloid Leukemia1
  • Refractory Chronic Myelomonocytic Leukemia1
  • Relapsed Myelodysplastic Syndromes1

Activity Timeline